A review of oral antiretroviral therapy for the treatment of chronic hepatitis B

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1271-1286

  Hynicka, Lauren M ^a   Yunker, Nancy ^b   Patel, Punam H ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adefovir; Chronic hepatitis B; Clevudine; Emtricitabine; Entecavir; Lamivudine; Nucleoside inhibitor; Nucleotide inhibitor; Pradefovir; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PRADEFOVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ABDOMINAL PAIN; ASTHENIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; LOW DRUG DOSE; MONOTHERAPY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARYNGITIS; PRIORITY JOURNAL; RASH; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIREMIA; VIRUS LOAD; VIRUS RESISTANCE; VOMITING; ANTIVIRAL RESISTANCE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; VIRAL LOAD;

EID: 77954593322     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M590     Document Type: Review

References (89)

1. Dienstag J. Hepatitis B virus infection. N Engl J Med 2008;259;1486-500. DOI 10.1056/NEJMra0801644
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009 (AASLD Practice Guidelines). Hepatology 2009;50:1-36. DOI 10.1002/hep.00000
3. Corey RL. Update on pharmacotherapy of chronic hepatitis B and C. In: Chessman KH, ed. Gastroenterology I and II and nutrition - PSAP VI, book 9. 6th ed. Kansas City, MO: American College of Clinical Pharmacy, 2009:1-24.
4. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006;44:593-606. DOI 10.1016/j.jhep.2006.01.001 (Pubitemid 43227885)
5. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-63. DOI 10.1056/NEJM199910213411702
6. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96. DOI 10.1002/hep.510290321
7. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7. DOI 10.1002/hep.510270628
8. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22. DOI 10.1053/j.gastro.2003.09.033
9. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:751-7. DOI 10.1053/jhep.2001. 27563
10. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26. DOI 10.1053/jhep.2002.33894
11. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17. DOI 10.1053/gast.2003.50013
12. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72. DOI 10.1002/hep.510300221
13. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303.
14. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006;26:162-70. DOI 10.1055/s-2006-939758
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50:661-2. DOI 10.1002/hep.23190
16. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008;22:1399-410. DOI 10.1097/QAD.0b013e3282f8b46f
17. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10. DOI 10.1056/NEJMoa051285
18. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007;13:4264-7.
19. Yao G, Chen CW, Lu WL, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007;1:365-72. DOI 10.1007/s12072-007-9009-2
20. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-21. DOI 10.1056/NEJMoa051287
21. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44. DOI 10.1053/j.gastro.2007.08.024
22. Yao G, Chen CW, Lu WL, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2008;2:486-93. DOI 10.1007/s12072-008-9088-8
23. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49. DOI 10.1053/j.gastro.2006.04.007
24. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastrol Hepatol 2008;23:1320-6. DOI 10.1111/j.1440-1746.2008.05455.x
25. Kurashige N, Ohkawa K, Hiramatsu N, et al. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-70. DOI 10.1007/s00535-009- 0076-0
26. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-95. DOI 10.1016/j.jhep.2008.10.017
27. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9. DOI 10.1002/hep.22658
28. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. DOI 10.1002/hep.21422
29. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. DOI 10.1002/hep.21513
30. Tong CW, Mullen JE, Wong T. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. J Antimicrob Chemother 2009;64:875-7. DOI 10.1093/jac/dkp283
31. Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naïve chronic hepatitis B. Hepatol Int 2009;3:403-10. DOI 10.1007/s12072-008-9109-8
32. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. J Antimicrob Chemother 2007;51:902-11. DOI 10.1128/AAC.00833-06
33. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;30:1064-71. DOI 10.1002/hep.23145
34. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16. DOI 10.1056/NEJMoa020681
35. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16. DOI 10.1002/hep.21225
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. DOI 10.1056/NEJMoa021812
37. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8. DOI 10.1002/hep.22414
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81. DOI 10.1056/NEJMoa042957
39. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51. DOI 10.1053/j.gastro.2006/09.020
40. Chang TT, Schiffman M, Tong M, et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) (poster 424). Presented at: 39th Annual Meeting of the European Association for the Study of the Liver, April 14-18, 2004, Berlin, Germany.
41. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-60. DOI 0.1002/lt.20981
42. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7. DOI 10.1016/S0016-5085(03)00939-9
43. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-9. DOI 10.1016/j.jhep.2003.09.022
44. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005;42:17A.
45. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8. DOI 10.1002/hep.22414
46. Package insert. Viread (tenofovir). Foster City, CA: Gilead Sciences, November 2008.
47. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55. DOI 10.1056/NEJMoa0802878
48. Van Brommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5. DOI 10.1002/hep.20464
49. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102 (abstract). Hepatology 2007;46:80A.
50. Heathcote EJ, Gane E, DeMan R, et al. A randomized double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): study GS-US-174-0103 (abstract). Hepatology 2007;46:861A.
51. Poggio PD, Zaccanelli M, Oggionni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J Gastroenterol 2007;13:4096-9.
52. Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 2006;5:1-4. DOI 10.1186/1476-5926-5-1
53. Van Brommel F, Vernhard Z, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-25. DOI 10.1002/hep.21253
54. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-8. DOI 10.1016/j.jhep.2007.09.202
55. Heathcote EJ, Gane E, deMan R, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B: study 103. Presented at: 13th International Symposium on Viral Hepatitis and Liver Disease, 2009.
56. Neff GW, Nery J, Lau DTY, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004;38:1999-2004. DOI 10.1345/aph.1E280
57. Trojan J, Stuermer M, Teuber G, Berger A, Gaust D. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? Gut 2007;56:436. DOI 10.1136/gut.2006.108928
58. Deterding K, Manns MP, Wedemeyer H. Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy? J Hepatol 2008;49:862. DOI 10.1016/j.jhep.2008.08.001
59. Hann HW, Chaw HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int 2008;2:244-9. DOI 10.1007/s12072-008-9045-6
60. Pastor R, Habersetzer F, Fafi-Kremer S, et al. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naïve patients. World J Gastroenterol 2009;15:753-5.
61. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95. DOI 10.1053/j.gastro.2008.10.026
62. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88. DOI 10.1056/NEJMoa066422
63. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20. DOI 10.1016/j.jhep.2008.12.019
64. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-54.
65. Marcellin P, Chan HL, Lai CL, et al. 76 week follow up of HBeAg positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine (abstract 124). J Hepatol 2007;46:S55.
66. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009;81:147-55. DOI 10.1016/j.antiviral.2008.10.008
67. Package insert. Emtriva (emtricitabine) Foster City, CA: Gilead Sciences, May 2008.
68. Gish RG, Leung NW, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-40. DOI 10.1128/AAC.46.6.1734-1740.2002
69. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005;43:60-6. DOI 10.1016/j.jhep.2005/02.017
70. Lim SG, Ng TM, King N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166:49-56. DOI 10.1001/archinte.166.1.49
71. Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006;4:549-61. DOI 10.1586/14787210.4.4549
72. Marcellin P, Mommeja-Martin H, Sacks SL, et al. A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-8. DOI 10.1002/hep.20257
73. Lim SG, Leung N, Hann HWL, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008;27:1282-92. DOI 10.1111/j.1365-2036.2008.03686.x
74. Lee HS, Chung YW, Lee KS, et al. A 12 week clevudine therapy showed potent and durable antiviral activity in HBe-positive chronic hepatitis B. Hepatology 2006;43:982-8. DOI 10.1002/hep.21166
75. Lee KS, Byun KS, Chung, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007;50:296-302. DOI 10.1159/000105442
76. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8. DOI 10.1002/hep.21629
77. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8. DOI 10.1002/hep.21800
78. Ko SY, Kwon SY, Choe WH, Kim BK, Kim KH, Lee CH. Clinical and virologic responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labeled prospective study. Antivir Ther 2009;14:585-90.
79. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-6. DOI 10.1002/hep.22959
80. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-34. DOI 10.1002/hep.22959
81. Fleische RD, Lok ASF. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51:787-91. DOI 10.1016/j.jhep.2009.06.011
82. Dose-ranging study of pradefovir with compensated hepatitis B. http://www.clinicaltrials.gov/ct2/show/NCT00230503 (accessed 2010 Mar 22).
83. Open-label treatment extension study for patients who complete study RNA200103-201. http://www.clinicaltrials.gov/ct2/show/NCT00230490 (accessed 2010 Mar 22).
84. Brunell MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8. DOI 10.1002/hep.20723
85. Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10. DOI 10.1128/AAC.48.10.3702-3710.2004
86. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok ASF. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-8. DOI 10.1016/j.jhep.2007.12.006
87. Santos SA, Uriel AJ, Park JS, et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006;18:1247-53. DOI 10.1097/01.meg.0000243877.17444.5e
88. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008;48:923-31. DOI 10.1016/j.jhep.2008.02.019
89. Lim SG, Krastev Z, Ng TM. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in the treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006;50:1642-8. DOI 10.1128/AAC.50.5.1642-1648.2006